Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session 1

1230 - A global Phase II study of Olmutinib (HM61713) in patients with T790M-positive NSCLC after failure of first-line EGFR-TKI (412O)

Date

18 Nov 2017

Session

Proffered paper session 1

Topics

Cytotoxic Therapy;  Clinical Research;  Non-Small Cell Lung Cancer

Presenters

Keunchil Park

Citation

Annals of Oncology (2017) 28 (suppl_10): x124-x143. 10.1093/annonc/mdx671

Authors

K. Park1, P.A. Jänne2, C. Yu3, L. Bazhenova4, L. Paz-Ares5, E. Baek6, O. Han6, K.Y. Hong6, H. Kwon6, Y. Kim6, S.R. Kim6

Author affiliations

  • 1 Division Of Hematology-oncology, Department Of Medicine, Samsung Medical Center, 06351 - Seoul/KR
  • 2 Medical Oncology, Dana-Farber Cancer Institute, 2215 - Boston/US
  • 3 Department Of Internal Medicine, National Taiwan University Hospital, Taipei/TW
  • 4 Medicine, Moores UCSD Cancer Center, 92093 - La Jolla/US
  • 5 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 6 Clinical Research, Hanmi Pharmaceutical Co., Ltd, Seoul/KR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1230

Background

Olmutinib (HM61713) is an oral EGFR mutant specific tyrosine kinase inhibitor (TKI) which has shown modest clinical activity and tolerability in patients with EGFR TKI pretreated NSCLC harboring a T790M mutation in a phase I study. The global Phase II trial was designed to evaluate the efficacy and safety of olmutinib 800mg monotherapy in patients with T790M-positive NSCLC.

Methods

Patients received olmutinib 800 mg/day in 21-day cycles. Primary endpoint was centrally confirmed objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), disease control rate (DCR), and safety. This study was conducted at 68 sites in 10 countries (Korea, Malaysia, Taiwan, the Philippines, Australia, Italy, Spain, Germany, US and Canada).

Results

162 patients (median age: 63) were enrolled in the study. After median 5.9 months of follow up, median treatment duration was 5.3 months (range: 0.03-13.01). Among 115 patients evaluable for independent reviewer response assessment, 59 (51.3%) patients achieved objective response, including 51 (44.4%) patients with confirmed response. Median PFS was 6.9 months (95% CI 5.8–not reached) and DCR was 87.8% (101/115). In post-hoc subgroup analysis, ORR was 43.3% (95% CI 30.6-56.8) in patients with brain metastases and 45.5% (95% CI 32.0-59.5) without brain metastases at baseline. Median PFS in patients with brain metastases (6.8 months; 95% CI 5.4-not reached) was similar to that in patients without brain metastases (9.5 months; 95% CI 5.8-not reached). In this study, the most common treatment-related AEs were diarrhea (37.7%), hyperkeratosis, nausea, and rash (25.3% of each). The proportion of patients with treatment-related AEs (Grade3) was 45.1% and 9 (5.6%) patients discontinued treatment. Dose reductions to 600mg and to 400mg were reported in 54 (33.3%) patients and in 7 (4.3%) patients, respectively. One case of toxic epidermal necrolysis (TEN) with fatal outcome was reported.

Conclusions

Olmutinib showed modest activity with tolerable safety profile in patients with T790M+ NSCLC who had previously received an EGFR TKI. Optimal dose of olmutinib is being determined by additional translational studies, to produce more improved therapeutic outcome in phase III clinical trials.

Clinical trial identification

NCT02485652.

Legal entity responsible for the study

Hanmi Pharmaceutical Co., Ltd.

Funding

Hanmi Pharmaceutical Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.